Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6813—Hybridisation assays
  • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6813—Hybridisation assays
  • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
  • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2600/00—Oligonucleotides characterized by their use
  • C12Q2600/158—Expression markers

Definitions

• the invention relates to cosmetic skin treatment regimens comprising administration of electrically conducted radio frequency current through skin to provide benefits to skin and further relates to genomics based assessment of the benefits and treatments for monitoring, screening and optimizing the skin treatment regimens.
• EM electromagnetic
• Treatment of skin to avoid or reduce effects of intrinsic chronological and extrinsic environmental aging of skin is a multi-billion dollar commercial industry underpinned by even greater dollar investment in the development and validation of new technologies.
• Administration of electromagnetic (EM) energy to skin via application to the surface of skin has been known for decades and implemented in a wide range of forms and through a variety of delivery devices.
• EM-based skin treatment methods may be divided into ablative and nonablative procedures although both exploit the thermolytic effect of EM energy application.
• a variety of products are available to consumers to improve the condition of skin and to delay and/or prevent typical signs of aging. Such signs include, for example, fine lines, wrinkles, hyper-pigmentation, shallowness, sagging, dark under-eye circles, puffy eyes, uneven skin tone, enlarged pores, diminished rate of epidermal cell turnover, and abnormal desquamation or exfoliation.
• signs include, for example, fine lines, wrinkles, hyper-pigmentation, shallowness, sagging, dark under-eye circles, puffy eyes, uneven skin tone, enlarged pores, diminished rate of epidermal cell turnover, and abnormal desquamation or exfoliation.
• the wide variety of available products and the advancements in skin care technology still fail to produce the desired results, and some feel the need to turn to more invasive medical procedures.
• Ablative procedures such as ablative laser have proven to be effective methods for gross morphological resurfacing or removal of skin, such as in scar and tattoo removal procedures, and have also proven effective for treating and improving appearance of aged and photo-damaged skin.
• ablative procedures are effective for improving the appearance of fine lines and wrinkles in the cosmetically vulnerable perioral and periorbital areas of facial skin
• major disadvantages include prolonged periods of healing and recuperation which impose a seriously compromised cosmetic appearance to the consumer for undesirably long time periods.
• the potential side effects of infection, scarring and pigmentation irregularities which may result are often considered cosmetically unacceptable to consumers in particular where facial skin is implicated.
• Selective photothermolysis of skin tissue is a widely practiced cosmetic treatment form, in particular in treatments comprising administration of monochromatic laser energy and broad spectrum intense pulsed light (IPL) energy.
• optical energy is applied directly to the surface of the skin and penetration relies on transmission through the epidermis and absorption in the dermis.
• Dark skin and hyper-pigmented spots on the epidermis may impede transmission and hinder efficacy of the treatment by absorbing energy, and may also result in overheating of the pigmented areas resulting in blistering, burning, and other cosmetically undesirable effects.
• radio frequency (RF) current As an alternative to EM-based thermolysis, electrically conducted radio frequency (RF) current has also been investigated as a cosmetic skin treatment modality.
• RF current and pulsed radio frequencies (pRF) in the medicinal arts is known, although the use of RF current as a nonablative skin rejuvenation technology for self-delivery by consumers is still relatively innovative.
• pRF pulsed radio frequencies
• a transfer of biopolar RF current takes place through two electrodes that are applied directly to the skin. The current, therefore, runs directly through the dermal layer conducted from electrode to electrode, distinguishing it from application of EM energy which is focused through the epidermis and limited by factors which affect wavelength penetration depth.
• RF current administration theoretically appears to offer significant skin treatment advantages over EM energy application.
• electrically conducted RF energy is chromophore-independent, which avoids complications and efficacy problems relating to the existence of an absorption differential between pigmented and non-pigmented skin and the resulting problems in treating darker skin, which has more energy- absorbing melanin and lighter skin, which may reflect optical wavelengths.
• consistency of results is compromised and thermal control in chromophore-containing skin remains problematic.
• RF current administration to skin at energy levels which may provide thermal treatment efficacy, however, is plagued by an inability by investigators to optimize parameters to achieve a desired benefit in the absence of undesirable skin damage.
• RF current is delivered through the dermal tissue below the skin surface, whereas effect-monitoring by temperature or moisture sensors is limited to the accessible surface of skin.
• RF current impedance is a function of tissue composition and various skin tissue attributes including collagen density and integrity, hydration level, and the like.
• RF has also been suggested and investigated as useful for cosmetic skin treatment in conjunction with targeted optical energy application.
• the RF is used adjunctively to the optical energy and is applied in accordance with some parameter of the optical energy.
• EOSTM Electro-optical synergy
• the authors focus on a coordinating pulse frequency between the RF current and the optical energy and suggest that synergy exists between these energy forms which may permit use of lower, less invasive levels of optical energy and further suggest that side effects associated with RF application alone are reduced or avoided by the combined protocol.
• the regimens which employ these devices include means to mechanically cool the skin in response to overheating, or to prevent overheating.
• U.S. Published Application No. 2008/0033516 Al to Altshuler discloses "temperature controlled photobiostimulation" of skin tissue which involves a combination of heating skin to a target depth and irradiation of a target area with electromagnetic radiation.
• Altshuler notes the existing technologies of low-level light, low-level laser, monochromatic and quasi-monochromatic photostimulation based skin treatment methods, which are generally thought to increase ATP production, cellular proliferation and protein production, as well as trigger a growth response by induction of a low-grade inflammatory response, but notes reports of inconsistent results and lack of clinical confirmation of efficacy.
• Altshuler posits that application thermal energy may enhance the photostimulatory response.
• Altshuler teaches that hyperthermia of a volume of skin may be achieved by any known source capable of raising the temperature of the volume to preferable between 37° and 45 °C, and specifically exemplifies heating by hot air, AC or DC electrical current, use of a conductive heat source, ultrasound or microwave radiation or any suitable wavelength or wavelengths of EM radiation in the range of 380-2700 nm. In all Altshuler embodiments, however, EM energy is relied upon to achieve the desired treatment effect.
• Altshuler teaches that heat provides synergistic enhancement of the desired effects of photostimulation, but also suggests that heat in the absence of EM may result in undesirable biostimulation such as slowing repair of radiation-induced DNA damage, production of heat shock proteins, which build tolerance to subsequent heat applications, and modification of enzymatic processes including those involved in skin tissue regeneration and repair and generally teaches away from heat in the absence of light as a skin treatment modality.
• Altshuler does not suggest how to overcome deficiencies relating to an inability to assess or monitor sub-epidermal skin conditions.
• the consumer experience is also important when designing a device, a composition and a regimen.
• sonograms are commonly performed procedures and provide an enormous medical benefit.
• the gel used in sonogram procedures is thick and difficult to remove causing consumer discomfort.
• energy delivery devices heat the exterior skin too quickly or too hot causing an unpleasant consumer experience.
• the present inventors investigated and determined a genetic fingerprint for the effect of electrically conducted RF-current on skin tissue and have developed inventive gene chips and methods employing those gene chips to provide safe and effective RF current based treatment regimens and treatment screening protocols.
• the present inventors surprisingly discovered that optimization of RF-current based treatments provides benefits relating to collagen synthesis and provides certain damage-induced benefits which stimulate dermal remodeling, while avoiding a more problematic damage-induced inflammatory cytokine response.
• the RF current based treatment regimens in accordance with the instant invention do not require supplementary energy delivery and specifically do not include administration of electromagnetic (EM) energy outside the radio wavelength portion of the EM radiation spectrum, and do not require mechanical surface cooling.
• EM electromagnetic
• One embodiment of the invention is directed to gene panels comprising genes regulated in mammalian skin in response to generation of a radio frequency current in a tissue volume of the mammalian skin sufficient to heat the tissue volume to a treatment temperature.
• Genes of the panels are selected from Table 1 and/or Table 2 with the proviso that at least one gene is selected from Table 3.
• Aspects include microarrays and genetic signatures based thereon.
• Another broad embodiment is directed to methods for providing a benefit to mammalian skin, the benefit comprising inducing collagen formation and/or dermal remodeling in a dermal layer of the mammalian skin in the absence of a skin-damaging inflammatory cytokine response, the method comprising generating a radio frequency current in a tissue volume of the mammalian skin for a treatment cycle sufficient to heat the tissue volume to a treatment temperature while avoiding an upregulation in expression of genes listed in Table 3.
• the energy delivery device is ostensibly designed to provide a benefit to skin by heating the skin and may be assessed by a method comprising: treating the skin by application of the energy delivery device; extracting mRNA from a sample of the treated skin; and generating an expression profile for a gene panel according to the invention.
• Facial skin treatment regimens may also be screened or assessed for efficacy in providing a collagen and/or dermal remodeling benefit to mammalian skin without stimulating a skin- damaging inflammatory cytokine response according to another embodiment.
• the method comprises: treating facial skin according to a treatment regimen; extracting mRNA from a sample of the treated facial skin; generating a gene expression profile for a gene panel according to the invention; comparing the gene expression profile to a reference profile; and determining that the facial treatment regimen is efficacious where the expression profile reflects upregulation of genes selected from Table 1 and/or Table 2 and a substantial lack of regulation of genes selected from Table 3.
• cosmetic actives and/or compositions may be similarly screened or assessed for providing benefits according to the invention or for synergism with the treatment methods of the invention.
• Figure 1 is a schematic representation of naturally occurring damage and repair cycle in human skin
• Figures 2A, 2B illustrate the properties of Human Collagen
• Figure 3 is a schematic of Biological Model of RF current administration efficacy
• Figures 4A, 4B are the 24 hour average fold-change for compilation genes
• Figures 5A, 5B are the 24 hour average fold-change for exemplary genes
• Figures 6A, 6B are the 1 month average fold-change for compilation genes
• Figures 7A, 7B are the 1 month average fold-change for exemplary genes
• Figures 8A, 8B are two graphs of RF simple heat transfer
• Figure 9 is a schematic of RF simple heat transfer
• Figure 10 is a schematic of the Crow's Feet area around a consumer's eyes;
• Figure 11 is zone A of a consumer's skin;
• Figure 12 is zone B of a consumer' s skin;
• Figure 13 is zone C of a consumer' s skin;
• Figure 14 is zone D of a consumer' s skin
• Figure 15 is zone E of a consumer's skin
• Figure 16 is zone F of a consumer' s skin.
• step (c) could be performed prior to or between steps (a) and (b).
• step (c) could be performed prior to or between steps (a) and (b).
• step (c) could be performed prior to or between steps (a) and (b).
• step (c) could be performed prior to or between steps (a) and (b).
• regulating the condition of skin means improving the condition of skin and/or prophylactically regulating the condition of skin, and includes, for example, protecting the tissue from ultraviolet radiation, and regulating the signs of skin aging.
• improving the condition of mammalian skin means effecting a visually and/or tactilely perceptible positive change in the appearance and feel of the tissue.
• Conditions that may be regulated and/or improved include, but are not limited to, one or more of the following: Reducing the appearance of wrinkles and coarse deep lines, fine lines, crevices, bumps, and large pores; thickening of skin (e.g., building the epidermis and/or dermis and/or sub-dermal layers of the skin, and where applicable the keratinous layers of the nail and hair shaft, to reduce skin, hair, or nail atrophy); increasing the convolution of the dermal-epidermal border (also known as the rete ridges); preventing loss of skin or hair elasticity, for example, due to loss, damage and/or inactivation of functional skin elastin, resulting in such conditions as elastosis, sagging, loss of skin or hair recoil from deformation; reduction in cellulite; change in coloration to the skin, hair, or nails, for example, under-eye circles, blotchiness (e.g., uneven red coloration due to, for example, rosacea),
• signs of skin aging include, but are not limited to, outward visibly and tactilely perceptible manifestations, as well as any macro- or micro effects, due to skin aging. These signs may result from processes which include, but are not limited to, the development of textural discontinuities such as wrinkles and coarse deep wrinkles, fine lines, skin lines, crevices, bumps, large pores, unevenness or roughness; flaking; dryness; loss of skin elasticity; discoloration (including under eye circles); blotchiness; shallowness; hyperpigmented skin regions such as age spots and freckles; keratoses; abnormal differentiation; hyperkeratinization; elastosis; collagen breakdown, and other histological changes in the stratum corneum, dermis, epidermis, vascular system (e.g., telangiectasia or spider vessels), and underlying tissues (e.g., fat and/or muscle), especially those proximate to the skin.
• textural discontinuities such as wrinkles and coarse deep wrinkles, fine lines,
• Pigmentation refers to an area of skin wherein the pigmentation is greater than that of an adjacent area of skin (e.g., a pigment spot, an age spot, and the like).
• personal care composition means compositions suitable for topical application on mammalian skin.
• the personal care compositions described herein may contain one or more skin care actives.
• skin care actives or “actives,” as used herein, means compounds that aid in regulating the condition of skin and of other mammalian skin, for example, by providing a benefit or improvement to the skin.
• Energy delivery device means any device used to deliver energy to mammalian skin and/or hair.
• delivery of energy means that the surface and/or layers of the skin are exposed to the energy emanating from the energy delivery device, where it may penetrate to desired layers of the skin, including the hair shaft and/or hair follicle.
• Continuous level means that the energy delivered by the device, or energy output, remains at an essentially constant level between the time of device activation and the time of device deactivation.
• Pulsed means that between the time of device activation and the time of device deactivation, the energy output varies in a predictable manner, characterized by periods of higher output (pulses) alternating with periods of lower output. The onset of pulses may be sudden or gradual. "Predictable” means that the pulse peak intensities, pulse shapes, pulse durations, and the temporal spacing between the pulses are substantially identical. The duration of the pulses and the time between pulses may vary.
• Hand-held means that the device is of a weight and dimension suitable for an average adult human to comfortably hold.
• the human skin may be divided into two major structural layers: the epidermis and the sub-epidermal or underlying dermis.
• the epidermis with the stratum corneum serves as a biological barrier to the environment.
• pigment-forming cells called melanocytes are present, which are the main determinants of skin color.
• the underlying dermis provides the main structural support of the skin. It is composed mainly of an extra-cellular protein called collagen. Collagen is produced by fibroblasts and synthesized as a triple helix with three polypeptide chains that are connected with heat labile and heat stable chemical bonds. When collagen-containing tissue is heated, alterations in the physical properties of this protein matrix occur at a characteristic temperature. Structural transition of collagen contraction and remodeling of the collagen matrix occurs with heat.
• Fig. 1 the boxes represent normal causes of collagen production. For many reasons, the increase of collagen in the skin, and the speed with which it is repaired and replaced contributes to fuller, healthier, and more attractive looking skin. Ongoing proliferation and dermal remodeling occur naturally, but unfortunately, these processes slow as we age. Collagen is also produced when skin is damaged, for example, after inflammation or insult from, for example, radiation from the sun.
• the circles in Fig. 1 represent some of the mechanisms by which collagen is formed and how its formation can be tracked. MMP and cytokine activity are just two measurable quantities that help track the collagen repair and replenishment cycle.
• Fig. 3 is a schematic of the dual action biological model for elure efficacy 20.
• Skin 21 is divided into three layers, the stratum corneum 30, the epidermis 32 and the dermis 34.
• the collagen remodeling and production of new collagen occurs in the dermis layer.
• Normal insult 22 to skin 21 occurs constantly and includes normal aging, UV insult, changes in pH, chemical insults and others. Normal insults 22 result in damaged collagen 24.
• normal low level inflammation 26 occurs that results in cytokine, HSP and HSF activity.
• repeated low level thermal energy yields increased MMP activity 36 results in the production of collagen fragments.
• the increase in heat causes an up regulation 38 of cellular activity that causes the formation and repair of collagen. Both mechanisms 36 and 38 result in the formation and remodeling of healthy collagen 28.
• the dermal structure is predominantly comprised of collagen 1.
• Collagen is expressed as procollagen, a single stranded protein, by fibroblasts.
• Procollagen is clipped upon expression to collagen 1 and folded into a triple helix conformation called "tropocollagen”.
• RF model heating curves are illustrated in Figures 8A, 8B and 9.
• the dermal structure is predominantly comprised of collagen 1, 50, Figures 2A and 2B.
• Collagen is expressed as procollagen 52, a single stranded protein, by fibroblasts.
• Procollagen 52 is clipped upon expression to collagen 1 50 and folded into a triple helix conformation called "tropocollagen" 54. This process is illustrated in Figures 2A and 2B.
• Collagen crosslinking may be intramolecular (covalent or hydrogen bond) or intermolecular (covalent or ionic bonds).
• causes of collagen denaturation as a function of age include thermal energy insult, mechanical insult, effects of pH on collagenase and MMP rate, hydration status, and general disruption in the natural equilibrium of collagen microfibrils which may "zip” or "unzip,” making them vulnerable to MMP digestion. Although these represent multiple insult types, all are rate controlled by temperature. Further, the normal collagen turnover cycle may be regulated within a temperature range of ⁇ 37°C - 43°C.
• Dermal remodeling is a biophysical phenomenon that occurs at cellular and molecular levels.
• Molecular contraction or partial denaturization of collagen involves the application of an energy source, which destabilizes the longitudinal axis of the molecule by cleaving the heat labile bonds of the triple helix.
• stress is created to break the intermolecular bonds of the matrix. This is essentially an extra-cellular process, whereas cellular contraction requires a lag period for the migration and multiplication of fibroblasts into a damaged area.
• a healing response generally involves an initial inflammatory process, which consists of infiltration by white blood cells or leukocytes that dispose of cellular debris.
• Fibroblasts differentiate into contractile myofibroblasts, which are the source of cellular soft tissue contraction. Following cellular contraction, collagen is laid down as a static supporting matrix in the tightened soft tissue structure. The deposition and subsequent remodeling of this nascent scar matrix provides the means to alter the consistency and geometry of soft tissue for aesthetic purposes.
• laser delivery devices use specific wavelengths of light that penetrate the skin, bind to specific chromophores and, through a process called selective photothermolysis, remove various colors and pigments from the skin.
• the lasers are large, expensive pieces of capital equipment, only attack specific problems or colors in the skin, are prone to laser burns, scars, can cause hyper and/or hypopigmentation and may result in user and patient ocular injuries.
• Intense broad band light systems emit multiple wavelengths of light, and through selective photothermolysis, also improve skin discoloration and, through skin heating, non-specific skin texture improvement.
• the systems are also larger and expensive, the skin textures and wrinkle improvements are minimal and there is also the risk of skin burns, hypo or hyperpigmentation and scars.
• application of electromagnetic energy is achieved through the epidermis with penetration limited by pigmentation factors at the surface and composition of the dermal layer.
• Radio frequency technologies are also known in the art of skin treatment.
• RF technology uses electrical current to heat the dermis and stimulate production of collagen and elastin fibers that firm and tighten the skin.
• Substantial drawbacks exist, however, in the current state of the art due to an inability to optimize treatment parameters.
• RF current application creates a thermal gradient in the skin that is reverse to other thermal energy delivery technologies.
• Administration of RF current is conducted between electrodes placed some distance apart on the skin. The current is conducted between the electrodes, through the dermis so that the temperature of the dermis rises more rapidly than the temperature at the skin surface. Since most skin parameter measuring devices are designed for skin surface measurement, excessive heating of the dermis may occur before realization.
• the present inventors developed methods for assessing the effects of dermal administration of RF current.
• the present inventors screened a group of potential genes identified as involved in the dermal collagen matrix, dermal inflammation and remodeling, and in epidermal differentiation. Genetic signatures and gene chip constituents based on resultant genetic expression profiles were determined by analysis and inspection of differential regulation of the potential genes when subject to specific RF current treatment parameters, conditions and regimens.
• Energy delivered to and/or into layers of the skin may be in the form of RF energy, including, for example, radiofrequency waves and microwaves.
• RF energy devices are disclosed in the following U.S. Patent Nos.: 6,889,090; 6,702,808; 6,662,054; 5,569,242; 5,755,753; 6,241,753; 6,430,446; 6,350,276; 5,919,219; 5,660,836; 6,413,255; 6,228,078; 5,366,443; and 6,766,202.
• RF and treatment regimens comprising administration of RF current through the dermis may be designed for the first time in order to optimize the desired effects of RF treatment.
• the potential gene dataset could be reduced into three subsets with particular utility in optimizing treatment regimens to provide increase in dermal collagen and desired hormetic stress-induced dermal remodeling, in the absence of a more problematic inflammatory cytokine damage response.
• this represents the first time that genomics has been applied to cosmetic treatment employing RF current technology.
• the expression profiles reveal that controlled and optimized administration results in the provision of positive hormetic stress which initiates and sustains desirable dermal remodeling, while avoiding the traditional damage associated with undesirable biological effects.
• the present invention provides novel gene chips, genetic signatures, methods of screening and optimizable regimens based on these discoveries.
• Genes investigated as potential genes include genes associated with integrity of the dermal matrix (FBN1, FBLN1, TNXB, FN1, LOXL2, COL3A1, COL1A1, ELN and LOXL1), genes associated with dermal inflammation initiated remodeling (TIMP2, ILIA, TIMP1, TNF, MMP1, MMP9, MMP3, SOD2 and IL1B) and genes associated with epidermal barrier function (KRT2, KRT6A, CLDN1, LOR, FLG, IVL, DRT10, AQP3, and KRT14).
• Table 1 dermal markers
• Table 2 matrix remodeling markers, i.e. positive hormetic stress initiators
• Table 3 markers of an inflammatory cytokine response, i.e. damage outside the repair response.
• a genetic expression profile provides information about cellular response to a set of conditions. Genes contain the instructions for making messenger RNA (mRNA). At any given point in time, however, each cell makes mRNA from only a fraction of the genes it carries. A gene is referred to as being turned “on” if it is being used to produce mRNA and is otherwise referred to as being turned “off.”
• the term “regulation” refers to triggering a transcriptional status that is different from a gene's control status. For example, “up-regulation” may include merely turning on, or may refer to increasing a transcriptional rate over a base line rate derived from a control or reference condition.
• the relative amount of mRNA expressed in two or more experimental conditions is measured. Altered levels of mRNA suggest a changed need for the protein coded for by the mRNA. For example, increased transcription of enzyme catalysts or cofactors is observed in response to increased levels of the enzyme's substrate in the cellular environment.
• a gene expression profile includes those genes that demonstrate significant differences under changed experimental conditions. This is typically a subset of some dataset, which may include the entire genome.
• a group of genes whose combined expression pattern is uniquely characteristic to a given condition constitutes a gene signature of the condition.
• Gene signatures may be used, for example, to select patients which may benefit from a particular treatment, or to design treatment protocols to maximize a desired signature.
• Genetic expression profiles for the potential gene dataset may be determined using a microarray.
• Exemplary cDNA microarrays are commercially available and may be purchased from such companies as Agilent Technologies, Affymetrix Inc. (Santa Clara, Calif.), Nanogen (San Diego, Calif.) and Protogene Laboratories (Palo Alto, Calif.).
• Specific hybridization technology which also may be practiced to generate the expression profiles employed in the subject methods includes the technology described in U.S. Pat. Nos.
• an array of "probe" nucleic acids that includes a probe for each of the phenotype determinative genes whose expression is being assayed is contacted with target nucleic acids as set forth above. Contact is carried out under hybridization conditions, e.g., stringent hybridization conditions and unbound nucleic acid is then removed.
• hybridization conditions e.g., stringent hybridization conditions and unbound nucleic acid is then removed.
• the resultant pattern of hybridized nucleic acid provides information regarding expression for each of the genes that have been probed, where the expression information is in terms of whether or not the gene is expressed and, typically, at what level, where the expression data, i.e., expression profile, may be both qualitative and quantitative. Alternatively, the expression profile is determined by quantitative PCR or other quantitative methods for measuring mRNA.
• One embodiment of the invention provides a gene panel comprising genes regulated in mammalian skin in response to generation of a radio frequency current in a tissue volume of the mammalian skin sufficient to heat the tissue volume to a treatment temperature. At least one gene is selected from Table 1 or Table 2 and at least one gene is selected from Table 3. In specific embodiments at least one gene is selected from each of the three tables. All gene panels according to the invention are contemplated to include at least one gene from Table 3, since lack of expression shift in these genes indicates lack of a "bad" damage response. Probes may be designed to target each gene constituting a gene chip of the invention in order to construct very specific microarrays with utility in designing, screening, adapting or monitoring treatment regimens for the desired effect, or for validation of the treatment regimen in treated subjects. Microarrays comprising a set of immobilized nucleic acid probes capable of hybridizing to and detecting genes constituting a gene panel according to the invention are contemplated.
• a "probe” refers to an oligonucleotide, polynucleotide or DNA molecule, whether occurring naturally or produced synthetically, which is capable of specifically hybridizing to a nucleic acid with sequences complementary to the probe.
• the probes of the present invention refer specifically to the oligonucleotides attached to a solid support in the DNA microarray substrate.
• a probe may be either single-stranded or double-stranded.
• the probe typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides.
• the probes herein are selected to be complementary to different strands of a particular target nucleic acid sequence and therefore must be sufficiently complementary so as to be able to specifically hybridize with their respective target strands under a set of pre-determined conditions. Therefore, the probe sequence need not reflect the exact complementary sequence of the target.
• a non-complementary nucleotide fragment may be attached to the 5' or 3' end of the probe, with the remainder of the probe sequence being complementary to the target strand.
• non-complementary bases or longer sequences can be interspersed into the probe, provided that the probe sequence has sufficient complementarity with the sequence of the target nucleic acid to anneal therewith specifically.
• Another embodiment of the invention includes methods for providing a benefit to mammalian skin.
• the benefit comprises inducing collagen formation and/or dermal remodeling in a dermal layer of the mammalian skin in the absence of a skin-damaging inflammatory cytokine response and the method comprises generating a radio frequency current in a tissue volume of the mammalian skin for a treatment cycle sufficient to heat the tissue volume to a treatment temperature while avoiding an upregulation in expression of genes listed in Table 3.
• the RF current may be generated a plurality of times in one treatment cycle.
• Treat” and “treatment” and the like generally refer to obtaining a desired cosmetic or aesthetic effect, underpinned by a targeted biological response.
• Treatment covers treatment in a mammal, particularly a human, and includes: (a) preventing or avoiding development of a cosmetically undesirable skin condition, for example fine lines, wrinkles, hyper-pigmented spots, and other skin irregularities that result from either chronological or environmental aging or impact on the skin, (b) inhibiting, ameliorating or delaying appearance of a cosmetically undesirable skin condition; (c) reversing or causing regression of the cosmetically undesirable skin condition.
• One or more treatment cycles according to the invention may be conducted across a treatment period. Treatment cycles may be as short in duration as necessary to effectuate a desired response. In specific embodiments the treatment cycle is about one minute or less, while in other specific embodiments the treatment cycle is greater than about one minute. In other specific embodiments a treatment cycle lasts between about 1 and about 6 minutes and in other embodiments lasts between about 2 and about 6 minutes.
• a treatment period according to the invention comprises one or more treatment cycles and in specific embodiments is at least one week and comprises at least one treatment cycle. In other specific embodiments the treatment period is between one week and 12 weeks. In more specific embodiments the treatment period is between 3 and 8 weeks. In certain embodiments each week of a treatment period comprises between one and six treatment cycles, although it is understood in the art that this may vary with unique features of individual being treated.
• a treatment temperature defined herein as the temperature of the tissue volume through which the RF current is conducted, effectuates a skin surface temperature over the tissue volume of less than about 45 °C. In more specific embodiments the treatment temperature effectuates a skin surface temperature over the tissue volume of between about 37°C and about 43°C.
• Desired benefits according to the invention may be assessed by extracting mRNA from a sample obtained from the tissue volume through which the RF current is conducted; and determining an expression profile of a gene panel consisting of at least one gene selected from Table 1 and/or Table 2 and at least one gene selected from Table 3. A benefit is indicated where an expression profile reflects upregulation of genes selected from Tables 1 and/or 2 combined with substantially no change in expression of genes selected from Table 3 is indicative of a benefit being provided.
• Fold-change appears to provide the most reproducible results. Fold-change may be defined as the ratio of the mean control and mean treatment observations (or as the difference of the mean log control and mean log treatment data). A fold-change of 1, therefore, represents no change over the control observation.
• a positive fold-change indicates an increase in expression across a time period referred to herein as upregulation, and a negative fold change indicates a decrease in expression across a time period referred to herein as downregulation.
• the significance of a fold-change may be determined by ordinary statistical methods.
• the benefit may be optimized by adjusting the treatment temperature and/or other treatment parameters in response to the expression profile wherein upregulation of the genes selected from Table 1 and/or Table 2 is maximized while expression of genes selected from Table 3 is maintained at substantially no change.
• the treatment regimens of the invention may comprise maintenance treatments wherein a benefit is maintained beyond the treatment period by one or more maintenance treatments, each maintenance treatment comprising at least one maintenance cycle.
• the inventive skin treatment regimens contemplate application of thermal energy by electrically conducted RF current via a handheld RF current delivery device.
• Preferred RF delivery devices according to the invention deliver RF as a current electrically conducted between two electrodes placed as some distance from one another on the skin.
• the delivery device that effectuates the benefits of the invention conducts the radio frequency current through the tissue volume in the absence of electromagnetic radiation in the visible light or infrared frequencies of the electromagnetic spectrum and in the absence of supplemental monochromatic or polychromatic light sources directed toward the tissue volume, as well as in the absence of mechanical cooling.
• Certain embodiments of the invention provide the capability for assessing efficacy of any energy delivery device or combination of energy delivery technologies in providing benefits according to the invention.
• specific methods for assessing treatment efficacy of an energy delivery device designed to provide a benefit to skin by heating the skin comprise: treating the skin by application of the energy delivery device; extracting mRNA from a sample of the treated skin; and generating an expression profile for a gene panel according to the invention.
• RF current delivery devices exist comprising parameter specification tolerances capable of being dialed in to yield the expression profile according to the invention.
• a suitable device is manufactured by Syneron.
• An example of a device that is not designed to achieve the genomic response goals of the instant invention is a handheld personal use RF delivery device manufactured by Ultragen Ltd for distribution in Europe under the brand STOPTM.
• This device also illustrated in Example 3 for comparative purposes, fails to elicit the upregulation of genes in Tables 1 and 2.
• the device specifications are designed to accommodate a regimen that is based on provision of substantially less thermal energy applied over a larger skin area and may not reach the levels required to achieve the positive homeotic effect achieved by devices and regimens in accordance with the present invention.
• methods of screening a facial skin treatment regimen are provided.
• the methods are screened for efficacy in providing a collagen and/or dermal remodeling benefit to mammalian skin without stimulating a skin-damaging inflammatory cytokine response.
• the methods generally comprise treating facial skin according to a treatment regimen; extracting mRNA from a sample of the treated facial skin; generating a gene expression profile for a gene panel according to the invention; comparing the gene expression profile to a reference profile; and determining that the facial treatment regimen is efficacious where the expression profile reflects upregulation of genes selected from Table 1 and/or Table 2 and a substantial lack of regulation of genes selected from Table 3.
• the facial skin treatment regimen comprises generating a pulsed radio frequency current through a first tissue volume of the facial skin over a treatment cycle with a radio frequency current generating device.
• the treatment regimen may comprise moving the radio frequency current generating device and generating a pulsed radio frequency current through a second tissue volume of the facial skin during the treatment cycle.
• periauricular skin facial skin around the ear, known as periauricular skin, is close in structure to the treatment target areas but not readily visible in the case of blemishes which may result from minor biopsy procedures.
• the required sample is obtained by biopsy of treated periauricular skin and the reference is obtained by biopsy of pre-treated or non-treated periauricular skin.
• the pre-treated or non-treated periauricular reference skin comprises skin substantially adjacent to the treated periauricular skin.
• the expression profile of genes selected from Table 1 and/or Table 2 reveals a fold-change over the reference that is statistically greater than one.
• the instant invention may provide benefits to skin other than facial skin, however facial skin is highlighted in illustrative examples because it poses the greatest cosmetic treatment challenges in that it manifests most readily the effects of both chronological and environmental aging and damage, and is initially thinner and more vulnerable than skin over other areas of the body. Further, facial skin is an area of paramount aesthetic significance to consumers of cosmetic treatment technologies.
• the benefit provided by application of RF-current may be augmented or enhanced by application of a cosmetic active or composition to the facial skin in conjunction with generating the pulsed radio frequency current.
• the active or composition may have a potentiating or synergistic effect on the gene expression profiles according to the invention.
• suitable cosmetic actives include Retinol Propionate and derivatives thereof, caffeine, Hyaluronic Acid, and generally plant extracts.
• Screening methods according to the invention comprise substantially the same parameters as treatment methods according to the invention with respect to treatment cycles, treatment periods, treatment temperatures and delivery devices, adjusted for desired screen tolerances.
• a gene signature of differentially expressed genes suitable for identifying a cosmetic skin benefit comprises induction of collagen formation and/or dermal remodeling in a dermal layer of mammalian skin in the absence of a skin-damaging inflammatory cytokine response, the genetic signature comprising at least one gene selected from each of Table 1, Table 2, and Table 3.
• a gene signature is a subset of genes obtained from a dataset of genes related to a particular characteristic, trait or biological function.
• Gene signatures may be obtained from all or a part of a gene dataset, and signatures according to the invention may comprise information from at least about two genes, or any number of genes up to the number constituting the total dataset.
• the method of the present invention comprises the step of applying a first personal care composition and optionally a second personal care composition to an area of mammalian skin.
• the first and second personal care compositions may be in a variety of forms, including but not limited to lotions, creams, serums, foams, gels, sprays, ointments, masks, sticks, moisturizers, patches, powders, and/or wipes.
• the first personal care composition is applied prior to and/or during delivery of energy.
• the second personal care composition is applied after the application of the first composition and the delivery of energy.
• the method of the present invention may comprise the step of applying a third personal care composition to the skin, wherein the third composition comprises a conditioning agent.
• the third personal care composition is applied prior to application of the first personal care composition.
• the third personal care composition is applied at least 24 hours prior to the delivery of energy.
• the first personal care composition is applied twice daily and energy is delivered once daily, alternatively once weekly, and alternatively once monthly.
• the first personal care composition is applied to the skin twice daily and energy is delivered to the skin once weekly.
• the first, second and third personal care compositions may contain a variety of ingredients, non-limiting examples of which may be found in The CTFA International Cosmetic Ingredient Dictionary and Handbook, Tenth Edition (2004).
• compositions of the present invention may comprise from 50% to 99.9% of a dermatologically acceptable carrier.
• the carrier of the present invention is in the form of an emulsion.
• emulsions generally contain an aqueous phase and an oil phase.
• the oils may be derived from animals, plants, or petroleum, may be natural or synthetic, and may include silicone oils.
• Emulsion carriers include, but are not limited to, oil-in-water, water-in-oil, water- in-oil-in-water, and oil-in-water-in-silicone emulsions.
• the dermatologically acceptable carrier comprises an oil-in-water emulsion, and alternatively, a silicone-in-water emulsion.
• the emulsion further may comprise a humectant, for example, glycerin and a non- ionic, cationic and/or anionic emulsifier.
• a humectant for example, glycerin
• a non- ionic, cationic and/or anionic emulsifier for example, glycerin and a non- ionic, cationic and/or anionic emulsifier.
• Suitable emulsifiers are disclosed in, for example, U.S. Patent No. 3,755,560 issued to Dickert et al., U.S. Patent No. 4,421,769, issued to Dixon et al., and McCutcheon's Detergents and Emulsifiers, North American Edition, pages 317-324 (1986).
• compositions of the present invention can be employed to improve the condition of the skin.
• quantity of the personal care composition that is applied to the skin can vary depending on the bodily location and desired benefit. Exemplary quantities include from 0.1 mg/cm ⁇ to 40 mg/cm ⁇ . One useful application amount is 0.5 mg/cm ⁇ to 10 mg/cm ⁇ .
• a temperature change may be simultaneously induced in the skin or alternatively, in a composition applied to the surface of the skin. This temperature change is in addition to any temperature change induced by the delivered energy itself.
• the skin may be heated prior to delivery of energy, or alternatively, the skin may be cooled before, during, and/or after delivery of energy.
• regimen zones were developed that optimize size of the treatment area and the optimal treatment time were developed. It was discovered, contrary to the teachings in the art, that using the device over large areas is not the best treatment method. When too large an area is treated, the beginning portion can cool down and recover before the consumer sweeps over it again. If too small an area is treated the consumer risks overtreatment and unnecessary damage. Moreover, the treatment itself is work intensive for the consumer and to breaking the treatment into discreet chunks makes it easier for the consumer to fully comply with the regimen. Likewise, the personal care composition used with the device is much more appealing to the consumer if they can apply it to a small area, treat that area and then remove any remaining personal care composition. Putting the personal care composition on the entire face, or even half of the face, can render the treatment experience unpleasant. This, in turn, has a negative impact on consumer compliance.
• FIG 10 wherein crow's feet area 60 of consumer 62 is identified with a dashed circle and occur above and below eyes 64 and adjacent the outside corner of each eye. It is well known that crow's feet areas 60 are prone to wrinkle and fine line formation as human age and are subject to environmental insults.
• Figure 11 shows Zone A 70 wherein arrows within Zone A are showed to demonstrate a exemplary treatment path for the device (not shown). The times of treatment are given above.
• Figure 10 illustrates Zone B 72 which is over the same eye of consumer 62 and overlaps crow's feet area 60. Exemplary arrows are shown to illustrate a possible path of treatment.
• Zone A 70 and Zone B 73 By defining Zone A 70 and Zone B 73 in this manner crow's feet area 60 is treated twice as long as non-crow's feet portion of Zones A and B. This is an important discovery because most of the fine lines and wrinkles on a consumer' s face that need treating are in the crow's feet area.
• Figures 13 and 14 illustrate Zones C 74 and D 76 on the other eye 64 of the consumer 62. As one would expect, these treatment areas are substantially similar and treated in the same manner as Zones A and B.
• FIG. 15 and 16 An alternate treatment protocol is shown in Figures 15 and 16 wherein Zones E 80 and F 82 are shown on consumer 62.
• These "C" shaped treatment areas treat the crow's feet area 60, Figure 10, only once on each pass, but the longer "C” shaped treatment area allows for each area of skin that is treated to cool a bit before the device returns for another pass. Thus, consumer's comfort is increased, but the crow's feet area 60, Figure 10, is treated only during the one treatment cycle.
• a second personal care composition may optionally be used in conjunction with the above-described method.
• the second personal care composition may be used between successive treatment periods that employ the first personal care composition and thermal heat device.
• the second personal care composition preferably comprises at least one skin care active not present in the first personal care composition.
• This example illustrates treatment of the periauricular region of facial skin for purposes of conducting genomic and histological assessments. Therefore, all treatments are technician- administered in a clinical setting for control purposes. Treatments are administered to four zones within the treatment area for a total of 16 minutes with 4 minutes per zone, 3 times per week for six weeks.
• the protocol is according to a split face/neck study in a within-subject control design with the treatment applied only to the periauricular region of one side and a sham treatment consisting of gel plus an unpowered device applied to the corresponding periauricular region of the other side. Treatments are monitored with thermal imaging cameras to ensure that target skin surface temperatures of 40-43 °C are reached within the first minute and maintained but not exceeded during each 4 minute treatment.
• the treatment site is located and centered just below the ear.
• the site is approximately 1.5 inches wide and about 4 inches long. If an area of treated skin is too dry or gets too hot, extra gel may be applied.
• the face and neck of the subject are clean and free of lotions, perfumes and the like. Hair is clipped back from the treatment area.
• One pump (approximately 1.4 g gel) is applied to treatment site and spread evenly without rubbing.
• An additional pump of gel to the cheek above the treatment area may be applied as needed during treatment to cool skin if it gets too hot, as expressed by the subject.
• the device is turned on and a 4 minute timer is set.
• the device applicator head is applied to the skin and moved along the treatment site using a back and forth motion and a light touch. Connectivity is maintained while maneuvering the device head across the treatment area. Proper contact with the skin is indicated by a lens on the applicator which should continue to flash red to indicate contact.
• the thermal camera image is monitored during treatment. Within 30-60 seconds, the skin in the treatment area reaches the optimal temperature of 40-43°C. Color patterns on the thermal image indicate temperature. Generally, as the device warms up the applicator is moved rapidly across the skin to avoid discomfort from the rising temperature. As the treatment continues, movement is slowed to maintain ideal temperature. Subjects are warned that the device will feel warm, but will not burn them.
• the temperature is in excess of 43°C if the thermal image shows solid red areas. Temperature is controlled by increasing treatment speed in the back and forth motion, by slightly increasing the size of the treatment area, by alternating the back and forth motion with a figure eight pattern, or by adding more gel by touching the applicator head to extra gel deposited on the cheek for this contingency.
• the back and forth motion should be slowed until the bulk of the treatment area is at the target temperature.
• This example illustrates the relatively gentle biopsy protocol used to collect samples for assessment and monitoring purposes in accordance with certain aspects of the invention and support data disclosed herein.
• a clinical biopsy study was conducted using an RF-current delivery device in 30 adult female subjects. Treatments were provided in the periauricular (around the ear) region of the facial skin. Periauricular skin is known in the cosmetic arts as a suitable perorbital substitute. Treatments were clinically administered using a Syneron V8 device (see Example 3), and a four minute heating profile as the target profile. Subjects received treatment three times per week for a total of six weeks. Biopsies were conducted to inspect skin histology as a function of treatment, and to generate a genomics profile.
• One 4mm biopsy was taken from the periauricular area from both the right and left sides of the neck (this area is located just below the ear). Using a 30 guage sterile needle, an anesthetic containing 2% xylocaine with epinephrine is injected just under the skin to be biopsied. Once the subject indicates that the area is numb, an appropriate size punch biopsy is collected using standard aseptic techniques, followed by suture closure. A 20% aqueous solution of aluminum chloride is used from homeostasis, as needed. Following biopsy the punch site is monitored for normal healing and sutures are removed after 7 days.
• the biopsied tissue is split into two separate samples, one for gene expression testing and the other for histological evaluation.
• the sample is divided into equal halves in a line parallel to a line drawn from the stratum corneum to the dermis. Sample handling is in accordance with industry standards.
• RNA biomarker identification and analysis that underpins certain embodiments of the invention including gene chips, genetic signatures and discovery of the biological model that guides RF delivery regimen design.
• 4mm biopsies in accordance with Example 2 were taken from both sides of the face/neck just below the ear as described above 2 times, once at 24 hours post final treatment, and once at 4 weeks post treatment.
• the biopsied samples were transferred to 2 ml centrifuge tubes containing 1.5 ml tissue storage reagent (RNA/ «£er® solution, invitrogen, Life Technologies, Carlsbad, CA). Tubes were refrigerated overnight at 2-8°C. Storage reagent was removed and the samples were placed in a freezer at -80°C until processing. Just prior to processing, samples were removed from the freezer and 1.5 ml monophasic solution of phenol and guanidine isothiocynate (TRIzol® reagent, Invitrogen, Life Technologies, Carlsbad, CA) and one 3 mM Tungsten carbide bead (3 mM Tungsten Carbide beads, Qiagen, Catalog #69997) were added to each tube.
• tissue storage reagent 1.5 ml monophasic solution of phenol and guanidine isothiocynate (TRIzol® reagent, Invitrogen, Life Technologies, Carlsbad, CA) and one 3 mM Tungsten carbide
• the samples were immediately homogenized in a mixer mill (Quiagen Inc.) with four 3 minutes shades at 30/second, flipping the adapter after each. Samples were centrifuged for 10 minutes at 12,000 rpm to remove debris. The supernatant was then transferred to pre-spun Phase Lock gel heavy tubes (Phase Lock gel heavy tubes, Eppendorf, New York, NY, catalog #0032-005-152), 300 ⁇ , chloroform (Sigma) was added, and the tubes shaken vigorously without over-vortexing. The samples were centrifuged for 10 minutes at 12,000 rpm and the supernatant was thereafter transferred into new 2 ml centrifuge tubes.
• Phase Lock gel heavy tubes Phase Lock gel heavy tubes
• Binding conditions were adjusted by adding 800 ⁇ 70% ethanol, and the tubes were vortexed to mix and then spun briefly. 830 ml of the sample was transferred to an RNeasy mini spin column in a vacuum manifold, and a vacuum was applied. The remaining sample (approx. 830 mil) was transferred onto the same RNeasy column and a vacuum was applied. Contaminants were removed by sequentially pitpetting 700 ⁇ 1 and 500 ⁇ 1 of buffer RW1 onto the RNeasy column with vacuum applied after each rinse.
• the RNeasy spin column was transferred to a new 2mil collection tube and the tube was centrifuged for 2 minutes at 14,000 rpm, and the column was transferred into anew 1.5 ml collection tube. Residual ethanol was aspirated from the inside ridge of each column. Thirty ⁇ of pre -heated Rnase-free water was pipetted directly onto the RNeasy membrane and the membrane was incubated for 5 minutes and then centrifuged for 2 minutes at 14,000 rpm. The elute was then collected, providing ready-to-use RNA in water.
• RNA yield was determined using the RNA 6000 Nano LabChip® Kit #5065-4476, available from Agilent Technologies, Inc. of Santa Clara, CA.
• RNA was evaluated by one-step RT-PCR. For the RT-PCR biomarker analysis, RNA was diluted to a final concentration of 5 ng/well.
• RNA was converted to cDNA with an RT-PCR kit (QScriptTM One-Step Fast MGB qRT-PCR kit, available from Quanta Bioscience, Inc., Gaithersburg, MD). Five hundred nanograms of RNA was then mixed with the QScript enzyme/buffer mix and run on a thermal cycler according to kit instructions.
• QScriptTM One-Step Fast MGB qRT-PCR kit available from Quanta Bioscience, Inc., Gaithersburg, MD. Five hundred nanograms of RNA was then mixed with the QScript enzyme/buffer mix and run on a thermal cycler according to kit instructions.
• Expression fold change data for the 27 compilation genes listed above at the 24 hour and 4 week target times are set forth in Figures 4A, 4B and Figures 6A, 6B, respectively, above.
• Genes associated with the dermal matrix are grouped as 90 and 91
• the genes associated with dermal inflammation remodeling are grouped as 92 and 93
• the genes associated with epidermal differentiation are grouped together as 94 and 95.
• Fold change data for exemplary genes are set forth in Figures 5A collgen 1A1, 5B elastin, and Figure 7A collagen 1A1 and 7B elastin. Note the co-regulation between many of the collagenelAl genes and the elastin genes.
• the gene expression profile reflects a downstream upregulation in the translation products. Although the observed fold change may be relatively low, the sustained upregulation in synthesis of certain proteins and enzymes over an extended period of time is considered to confer substantially enduring cosmetic benefit to the skin.
• Simulgel INS 100 Sodium Acryloyldimethyl Thickener 3.00 1.08 0.0-3.0 taurate Copolymer
• Polysorbate 60 Surfactant 0.12 0.0-0.30 Water Vehicle 1.08 0.0-3.0
• Hexylene Glycol Hexylene Glycol 1.00 1.00 0.0-1.00
• Phenoxyethanol Phenoxyethanol 0.50 0.50 0.0-2.0
• Dissolvine NA2 S Disodium EDTA Chelating Agent 0.05 0.05 0.0-1.0
• the following is an exemplary personal care composition for use with the devices of the present invention.
• Fibrillins are structural components of 10-12 nm (SEQ extracellular matrix glycoprotein that serve extracellular calcium-binding microfibrils, which ID NO: as a structural component of 10-12 nm occur either in association with elastin or in
• FBLN1 A secreted glycoprotein that becomes Incorporated into fibronectin-containing matrix
• ECM laminin extracellular matrix
• ECM architecture in particular to those of basement membranes. Implicated in a role in cellular transformation and tumor invasion;
• TNXB A member of the tenascin family of Appears to mediate interactions between cells (SEQ extracellular matrix glycoproteins. The and the extracellular matrix.
• Substrate-adhesion ID NO: tenascins have anti-adhesive effects, as molecule that appears to inhibit cell migration.
• This protein is thought to function in matrix role in supporting the growth of epithelial tumors maturation during wound healing.
• FN1 fibronectin a glycoprotein present in a Fibronectins bind cell surfaces and various (SEQ soluble dimeric form in plasma, and in a compounds including collagen, fibrin, heparin, ID NO: dimeric or multimeric form at the cell DNA, and actin. Fibronectins are involved in cell 4) surface and in extracellular matrix. adhesion, cell motility, opsonization, wound
• Fibronectin is involved in cell adhesion and healing, and maintenance of cell shape.
• LOXL2 A member of the lysyl oxidase gene family.
• the prototypic member of the family is essential (SEQ to the biogenesis of connective tissue, encoding ID NO: an extracellular copper-dependent amine
• Type 1 is a fibril-forming collagen found in most 1 A1 whose triple helix comprises two alphal connective tissues and is abundant in bone, (SEQ chains and one alpha2 chain. cornea, dermis and tendon.
• ELN A protein that is one of the two components Major structural protein of tissues such as aorta (SEQ of elastic fibers.
• the encoded protein is rich and nuchal ligament, which must expand rapidly ID NO: in hydrophobic amino acids such as glycine and recover completely.
• proline which form mobile hydrophobic of the late arterial morphogenesis, stabilizing regions bounded by crosslinks between arterial structure by regulating proliferation and lysine residues. organization of vascular smooth muscle.
• LOXL1 A member of the lysyl oxidase gene family.
• the prototypic member of the family is essential (SEQ to the biogenesis of connective tissue, encoding ID NO: an extracellular copper-dependent amine
• TI P2 Inhibitors of the matrix metalloproteinases Has a unique role among TIMP family
• the encoded protein may be critical to the MMP-7, MMP-8, MMP-9, MMP-10, MMP-13, maintenance of tissue homeostasis by MMP-14, MMP-15, MMP-16 and MMP-19 suppressing the proliferation of quiescent tissues in response to angiogenic factors, and by inhibiting protease activity in tissues undergoing
• TI P1 Complexes with metalloproteinases such as Promotes cell proliferation in a wide range of (SEQ collagenases) and irreversibly inactivates them. cell types, and may also have an anti- ID NO: Also mediates erythropoiesis in vitro; but, apoptotic function. Transcription of this gene 11) unlike IL-3, it is species-specific, stimulating the is highly inducible in response to many
• MMP-1 MMP-2, MMP-3, MMP-7, MMP-8,
• metastasis Activated when cleaved by extracellular proteinases.
• a secreted enzyme which breaks down the interstitial collagens, types I, II, and III.
• N-terminal one quarter fragments Degrades tumor-associated tissue remodeling. May play fibronectin but not laminin or Pz-peptide an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. could play a role in bone osteoclastic resorption.
• SEQ family. This cytokine is produced by inflammatory response, and is involved in a variety ID NO: activated macrophages as a proprotein, of cellular activities, including cell proliferation, 15) which is proteolytically processed to its differentiation, and apoptosis.
• the induction of active form by caspase 1 (CASP1 /ICE) cyclooxygenase-2 (PTGS2/COX2) by this cytokine in the central nervous system (CNS) is found to contribute to inflammatory pain hypersensitivity.
• IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity.
• IL-1 proteins are involved in the inflammatory response, being identified as endogenous pyrogens, and are reported to stimulate the release of prostaglandin and collagenase from synovial cells
• TNF A multifunctional proinflammatory cytokine Involved in the regulation of a wide spectrum of (SEQ that belongs to the tumor necrosis factor biological processes including cell proliferation, ID NO: (TNF) superfamily and mainly secreted by differentiation, apoptosis, lipid metabolism, and 16) macrophages; binds to and thus function coagulation; Implicated in a variety of diseases, through its receptors TNFRSF1 A/TNFR1 including autoimmune diseases, insulin resistance, and TNFRSF1 B/TNFBR. and cancer. May have a neuroprotective function. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation
• IL1 A A member of the interleukin 1 cytokine Stimulates thymocyte proliferation by inducing IL-2 (SEQ family; produced by monocytes and release, B-cell maturation and proliferation, and ID NO: macrophages as a proprotein, which is fibroblast growth factor activity.
• IL-1 proteins are 17) proteolytically processed and released in involved in the inflammatory response, being

Applications Claiming Priority (2)

Publications (1)

Family

ID=44343224

Family Applications (1)

Country Status (8)

Families Citing this family (11)

Family Cites Families (37)

• 2011
  • 2011-04-19 EP EP11718568A patent/EP2561092A1/en not_active Withdrawn
  • 2011-04-19 JP JP2013506231A patent/JP2013527756A/ja active Pending
  • 2011-04-19 CA CA2795671A patent/CA2795671A1/en not_active Abandoned
  • 2011-04-19 CN CN201180019773.9A patent/CN102869789B/zh not_active Expired - Fee Related
  • 2011-04-19 BR BR112012026870A patent/BR112012026870A2/pt not_active IP Right Cessation
  • 2011-04-19 MX MX2012012235A patent/MX2012012235A/es not_active Application Discontinuation
  • 2011-04-19 WO PCT/US2011/033033 patent/WO2011133538A1/en active Application Filing
  • 2011-04-19 KR KR1020127026405A patent/KR20120137407A/ko not_active Application Discontinuation

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events